仁度生物
(688193)
| 流通市值：9.55亿 | | | 总市值：12.62亿 |
| 流通股本：3025.76万 | | | 总股本：4000.00万 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 44,815,148.38 | 164,412,273.1 | 117,098,308.04 | 80,029,969.73 |
| 营业收入 | 44,815,148.38 | 164,412,273.1 | 117,098,308.04 | 80,029,969.73 |
| 二、营业总成本 | 43,739,944.96 | 182,287,512.91 | 134,805,673.93 | 97,235,920.29 |
| 营业成本 | 8,713,080.04 | 30,610,426.46 | 21,409,391.87 | 14,840,933.81 |
| 税金及附加 | 244,779.04 | 965,105.53 | 701,195.81 | 469,753.46 |
| 销售费用 | 20,257,085.34 | 90,945,387.18 | 67,835,643.87 | 51,554,886.86 |
| 管理费用 | 7,223,829.28 | 26,768,089.51 | 21,041,294.04 | 14,501,820.94 |
| 研发费用 | 10,176,017.01 | 41,136,167.45 | 29,704,497.58 | 18,600,816.46 |
| 财务费用 | -2,874,845.75 | -8,137,663.22 | -5,886,349.25 | -2,732,291.23 |
| 其中:利息费用 | 110,231.74 | 431,196.7 | 407,401.02 | 299,688.52 |
| 其中:利息收入 | 2,555,151.45 | 8,724,874.07 | -5,601,640.77 | 3,040,452.08 |
| 加:公允价值变动收益 | 620,808.32 | 661,635.37 | -335,361.87 | 651,766.73 |
| 加:投资收益 | 974,191.98 | 6,923,912.48 | 6,592,662.48 | 3,314,360.59 |
| 资产处置收益 | - | -53,511 | -53,511 | - |
| 资产减值损失(新) | -357,326.04 | -1,275,623.92 | -853,904.11 | -664,933.05 |
| 信用减值损失(新) | -425,494.71 | -629,909.31 | -233,154.18 | -220,056.75 |
| 其他收益 | 1,486,340.57 | 17,690,949.26 | 1,306,434.9 | 1,306,434.9 |
| 营业利润平衡项目 | -0.01 | 0 | 0 | 0 |
| 四、营业利润 | 3,373,723.53 | 5,442,213.07 | -11,284,199.67 | -12,818,378.14 |
| 加:营业外收入 | 33,030.83 | 135,382.24 | 1.45 | 1.11 |
| 减:营业外支出 | 33,612.63 | 815,064.16 | 495,378.15 | 150,268.31 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 3,373,141.73 | 4,762,531.15 | -11,779,576.37 | -12,968,645.34 |
| 减:所得税费用 | -330,766.09 | -3,496,765.43 | -3,436,347.84 | -2,776,012.07 |
| 六、净利润 | 3,703,907.82 | 8,259,296.58 | -8,343,228.52 | -10,192,633.27 |
| 持续经营净利润 | 3,703,907.82 | 8,259,296.58 | -8,343,228.52 | -10,192,633.27 |
| 归属于母公司股东的净利润 | 3,703,907.82 | 8,259,296.58 | -8,343,228.52 | -10,192,633.27 |
| (一)基本每股收益 | 0.09 | 0.21 | -0.21 | -0.25 |
| (二)稀释每股收益 | 0.09 | 0.24 | -0.21 | -0.25 |
| 八、其他综合收益 | 68,675.78 | 621,345.98 | 1,202,726.7 | 1,514,771.35 |
| 归属于母公司股东的其他综合收益 | 68,675.78 | 621,345.98 | 1,202,726.7 | 1,514,771.35 |
| 九、综合收益总额 | 3,772,583.6 | 8,880,642.56 | -7,140,501.82 | -8,677,861.92 |
| 归属于母公司股东的综合收益总额 | 3,772,583.6 | 8,880,642.56 | -7,140,501.82 | -8,677,861.92 |
| 公告日期 | 2024-04-30 | 2024-04-30 | 2023-10-31 | 2023-08-01 |
| 审计意见(境内) | | 标准无保留意见 | | |